{"nctId":"NCT00660023","briefTitle":"A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on Dialysis","startDateStruct":{"date":"2008-08"},"conditions":["Anemia"],"count":124,"armGroups":[{"label":"Mircera in Renal Anemia","type":"EXPERIMENTAL","interventionNames":["Drug: Methoxy polyethylene glycol-epoetin beta"]}],"interventions":[{"name":"Methoxy polyethylene glycol-epoetin beta","otherNames":["CERA/Mircera"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults greater than or equal to (≥) 18 years of age\n* Chronic renal anemia\n* Continuous stable intravenous or subcutaneous maintenance epoetin or darbepoetin therapy during previous month\n* Regular long-term hemodialysis therapy with the same mode of dialysis for the previous 3 months\n\nExclusion Criteria:\n\n* Transfusion of red blood cells during previous 2 months\n* Poorly controlled hypertension\n* Significant acute or chronic bleeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)","description":"Reference Hb was determined individually per participant as the average of all Hb values during a pre-treatment stability assessment (Weeks -4 to -1). During the EEP (Weeks 18 to 24), participants provided a total of four blood samples for Hb monitoring while on treatment with CERA/Mircera. The average Hb during the EEP was calculated per participant and assessed against the reference value. The percentage of participants who had average Hb during the EEP in the target range of 10.0 to 12.0 g/dL and within ±1 g/dL of their individual reference Hb was determined as the primary endpoint. The 95 percent (%) confidence interval (CI) was calculated using the Pearson-Clopper method for exact confidence bounds.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Time-Adjusted Hb From Baseline to EEP","description":"Reference Hb was determined individually per participant as the average of all Hb values during a pre-treatment stability assessment (Weeks -4 to -1). During the EEP (Weeks 18 to 24), participants provided a total of four blood samples for Hb monitoring while on treatment with CERA/Mircera. The average Hb during the EEP was calculated per participant and assessed against the reference value. The mean change in Hb value between reference (i.e., \"Baseline\") Hb and the EEP average Hb was calculated and expressed in g/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Whose Hb Remained Within Target Range Throughout the EEP","description":"During the EEP (Weeks 18 to 24), participants provided a total of four blood samples for Hb monitoring while on treatment with CERA/Mircera. The percentage of participants who maintained each single Hb measurement in the target range of 10.0 to 12.0 g/dL was determined. The 95% CI was calculated using the Pearson-Clopper method for exact confidence bounds.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Time Spent in the Target Range for Hb During the EEP","description":"During the EEP (Weeks 18 to 24), participants provided a total of four blood samples for Hb monitoring while on treatment with CERA/Mircera. Time spent in the target range of 10.0 to 12.0 g/dL was defined as time from first on-target Hb to time of last known on-target Hb, as collected during the EEP. Time spent in the target range was averaged among all participants and expressed in days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.5","spread":"15.64"}]}]}]},{"type":"SECONDARY","title":"Mean Dose of Mircera/CERA During the Dose Titration Period (DTP) and EEP","description":"Study drug administration occurred monthly during the DTP (Weeks 0 to 16), which began with a pre-specified dose of Mircera/CERA according to the dose of ESA administered during Week -1. Subsequent doses could be adjusted throughout the study including during the EEP (Weeks 18 to 24) on the basis of Hb levels or other modification criteria. The dose received at each administration visit was averaged among all participants during the DTP and EEP and expressed in mcg.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":"39.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.3","spread":"69.43"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Required Any Dose Adjustment of Mircera/CERA During the DTP and EEP","description":"Study drug administration occurred monthly during the DTP (Weeks 0 to 16), which began with a pre-specified dose of Mircera/CERA according to the dose of ESA administered during Week -1. Subsequent doses could be adjusted throughout the study including during the EEP (Weeks 18 to 24) on the basis of Hb levels or other modification criteria. The percentage of participants who required a dose adjustment for any reason was calculated during the DTP and EEP.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Receiving Blood Transfusion During the DTP and EEP","description":"The number of participants who received blood transfusion during the DTP (Weeks 0 and 16) and EEP (Weeks 18 to 24) was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Blood Transfusions During the DTP and EEP","description":"The number of blood transfusion during the DTP (Weeks 0 and 16) and EEP (Weeks 18 to 24) was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":114},"commonTop":["Hypertension","Muscle spasm","Bronchitis"]}}}